Adbry Reviews: Real Results for Eczema Itch and Sleep

Adbry (tralokinumab) has built a solid track record as a biologic treatment for moderate-to-severe atopic dermatitis, with both clinical trials and real-world data showing meaningful improvements in skin clearance, itch, and quality of life for many patients. It works differently from the better-known dupilumab (Dupixent) by targeting only one inflammatory protein rather than two, and that narrower approach has both advantages and limitations worth understanding before starting treatment.

What Adbry Does in the Body

Adbry is a human monoclonal antibody that latches onto a specific immune signaling protein called IL-13 with high affinity, preventing it from activating its receptors and driving inflammation in the skin.¹ IL-13 is one of the central drivers of the itch-scratch cycle, skin barrier breakdown, and thickening that characterize eczema. Structural studies show that tralokinumab binds to two specific regions on the IL-13 molecule, physically blocking it from docking with either of its two receptor types.²

This matters practically because the main alternative biologic, dupilumab, blocks both IL-4 and IL-13 signaling by targeting a shared receptor component. Adbry’s selective approach leaves the IL-4 pathway untouched.³ Whether that narrower targeting is better or worse depends on the individual patient, but it does mean that Adbry and dupilumab are not interchangeable in every case, and switching from one to the other is a real option when the first choice underperforms.

What the Pivotal Trials Found

Adbry’s approval rested largely on two large, year-long trials called ECZTRA 1 and ECZTRA 2, each enrolling hundreds of adults with moderate-to-severe eczema. By week 16, roughly one in six to one in five patients on Adbry achieved clear or almost-clear skin (compared with about one in ten on placebo), and about a quarter to a third hit at least a 75% improvement in their eczema severity scores.⁴ Improvements in itch and sleep disruption appeared as early as the first week after treatment began.

Those headline numbers can look underwhelming at first glance, especially compared with the flashier response rates reported for some newer drugs. But clinical trials use strict criteria for “success” that do not capture everyone who genuinely benefits. A deeper analysis of the same two trials looked at patients who did not reach clear or almost-clear skin at week 16 and found that a third of them still achieved at least a 50% reduction in eczema severity on Adbry, compared with about 13% on placebo. More than 40% reported a meaningful improvement in quality of life even without hitting the top-line endpoint.⁵ In other words, even patients who would technically be classified as “non-responders” on the primary measure often experienced real, noticeable relief.

For patients who responded well at week 16, the majority maintained that response through a full year of treatment.⁶ That durability matters, since eczema is a chronic condition and a drug that works at four months but fades by eight is not especially helpful long-term.

How It Performs Outside of Clinical Trials

Clinical trials recruit carefully selected patients under controlled conditions, so the real test for any drug is what happens when ordinary dermatologists prescribe it to ordinary patients. On that front, Adbry’s real-world numbers are actually stronger than its trial results, which is unusual and encouraging.

A systematic review and meta-analysis pooling data from 19 real-world studies covering over 900 patients found that after 16 weeks on Adbry, about 82% achieved at least a 50% reduction in eczema severity, roughly 59% hit the 75% threshold, and about 26% reached a 90% improvement. The rate of conjunctivitis, one of the drug’s known side effects, was only about 3%.⁷ Those response rates are substantially higher than what the ECZTRA trials reported. The likely explanation is that real-world patients are allowed to use topical treatments alongside Adbry, which most people naturally do, whereas the pivotal trials tested Adbry as a solo treatment without additional creams or ointments.

One single-center study tracked 34 patients over a full year and found that 93% had clear or almost-clear skin at the 12-month mark, with no adverse events reported during that entire period. Every patient in the study reported subjective improvement in clearance, itch, and flare frequency.⁸ That is a small study, and small studies can be optimistic, but the pattern it shows aligns with the larger pooled data.

What Patients Actually Report About Itch, Sleep, and Daily Life

Skin clearance scores tell you what a dermatologist sees in the office, but patients care most about itch, sleep quality, and how the disease affects daily activities. A U.S. real-world study tracking patient-reported outcomes over six months found that itch scores dropped by about 39%, sleep interference dropped by 40%, and quality-of-life scores improved by 52%. About half to two-thirds of patients crossed the threshold for a “meaningful” improvement across these different measures.⁹

An interesting wrinkle in that data: patients who had never tried dupilumab before starting Adbry consistently did better than those who had switched from dupilumab. Among dupilumab-naive patients, about 66% reported meaningful improvement in sleep and about 76% in quality of life, compared with roughly 48% and 62% in the dupilumab-experienced group.¹⁰ That gap makes sense: people switching from dupilumab often had harder-to-treat disease or had already exhausted an easier-to-treat phase, so their starting point was tougher.

Separate real-world data following patients for up to nine months showed that itch, quality of life, and sleep continued to improve gradually between months three and nine rather than plateauing early.¹¹ If you start Adbry and feel only partially better at three months, staying the course may still yield further gains over the following half-year.

Side Effects and Safety Signals

Adbry’s safety profile is generally favorable. The most common side effects in trials were injection-site reactions and conjunctivitis, and the large majority of these were mild to moderate.¹² The real-world conjunctivitis rate of about 3% is lower than what some trials reported and substantially lower than the rates seen with dupilumab in many studies, though direct comparisons are tricky because the patient populations differ.

Eye problems deserve extra attention because they are the side effect that most often leads patients to reconsider their biologic. Conjunctivitis from IL-13 or IL-4/IL-13 blockers is usually manageable with lubricating eye drops, antihistamine drops, or in moderate cases, a short course of anti-inflammatory eye drops. Stopping the biologic is rarely necessary for conjunctivitis alone.¹³ Rarer and more serious eye complications have been reported, including a case of peripheral ulcerative keratitis, so new or worsening eye symptoms while on Adbry should prompt a visit to an eye doctor rather than just self-treating with over-the-counter drops.

Post-marketing surveillance based on the FDA’s adverse-event reporting system has identified several signals worth knowing about, including eye itching, dry eye, eye swelling, and a small number of reports of pneumococcal pneumonia and cutaneous T-cell lymphoma.¹⁴ Pharmacovigilance signals are not proof of causation; they flag patterns worth watching. Most adverse events occurred within the first month of starting treatment. The absence of serious systemic safety concerns through multiple years of real-world use is reassuring, particularly for a drug that many patients will take for years.

Adbry in Adolescents

Adbry was initially approved for adults, but a dedicated trial in adolescents (ages 12 to 17) with moderate-to-severe eczema has since expanded its use. That trial tested two doses, 150 mg and 300 mg, and both outperformed placebo by a wide margin. About 21% of adolescents on the 150 mg dose and 18% on 300 mg achieved clear or almost-clear skin at week 16, compared with only 4% on placebo. For a 75% reduction in eczema severity, the numbers were roughly 29% and 28% versus 6%.¹⁵

Among adolescents who responded at week 16 and continued treatment, more than half maintained their response through a full year. For those who were switched to open-label Adbry (meaning everyone knew they were getting the active drug), about a third had clear or almost-clear skin and nearly 58% hit the 75% severity reduction mark at week 52.¹⁶ The drug was well tolerated in this age group, and conjunctivitis rates did not increase over the full year of follow-up.

As with adults, the strict trial endpoints do not tell the whole story for teens. A further analysis of adolescents who did not reach clear or almost-clear skin at week 16 found that significant numbers still experienced at least a 50% eczema improvement and meaningful itch relief, with continued gains when treatment extended to a full year. About 40% of these initial “non-responders” who stayed on Adbry eventually reached a 90% severity reduction by week 52.¹⁷ The message for teens and their parents is similar to the one for adults: give it time, and partial early improvement can still turn into substantial long-term benefit.

How Adbry Stacks Up Against Other Options

Patients and doctors choosing among systemic treatments for eczema now have more options than ever, and the comparison that comes up most often is Adbry versus dupilumab. No head-to-head trial has been completed between the two, so all comparisons rely on indirect evidence. In general, dupilumab’s trial numbers for skin clearance are somewhat higher than Adbry’s, but the two drugs have not been tested against each other in the same patients under the same conditions, so the gap may be smaller than it appears on paper.¹⁸

JAK inhibitors (such as upadacitinib and abrocitinib) are the other major category. These oral medications tend to work faster, especially for itch relief, but carry a different safety profile that includes risks related to blood clots, cardiovascular events, and infections at higher rates than biologics. Clinical reviews note that biologics like Adbry and dupilumab offer advantages in long-term safety and durable disease control, while JAK inhibitors have the edge in speed.¹⁹ The choice often comes down to what you prioritize: rapid symptom relief with ongoing safety monitoring, or a slower ramp-up with a cleaner long-term safety picture.

One practical advantage of Adbry’s dosing schedule is worth noting. After the loading doses, Adbry is injected every two weeks, but patients who respond well can often step down to every four weeks. That reduced injection frequency is appealing for anyone who dislikes needles or juggles a complicated schedule.

Who Is Most Likely to Respond Well

IL-13 is not just Adbry’s target; it also functions as a biomarker. Higher IL-13 levels in the skin and blood are associated with more severe eczema, and tracking those levels can help predict whether a given patient is a good candidate for treatment and monitor how well the drug is working.²⁰ In practice, most dermatologists do not order IL-13 blood tests before prescribing Adbry, but the concept matters because it helps explain why some patients respond better than others.

A real-world analysis identified several factors that predict a weaker response. At the 12-week mark, patients who fared poorly tended to have higher baseline eczema severity, higher LDH (a general inflammation marker), and a higher ratio of eosinophils to lymphocytes in their blood. By 24 weeks, the picture shifted: older age, longer disease duration, and a history of previous systemic treatments (especially prior dupilumab or JAK inhibitors) predicted poorer outcomes.²¹ None of these factors are absolute deal-breakers, but they can help set realistic expectations. If you have tried multiple other systemic therapies without success, Adbry may still work, but the odds are somewhat lower than for someone starting biologic treatment fresh.

Vaccines While on Adbry

A common concern with any drug that modifies the immune system is whether it weakens vaccine responses. A dedicated 30-week trial tested this directly by vaccinating patients on Adbry with tetanus/diphtheria/pertussis and meningococcal vaccines. The immune responses were not meaningfully different from placebo: about 92% of Adbry patients mounted a good response to the Tdap vaccine (compared with 96% on placebo), and about 86% responded to the meningococcal vaccine (compared with 84% on placebo).²² You do not need to pause Adbry for routine vaccinations, including flu shots and standard boosters. Live vaccines are a separate question that your doctor should weigh on a case-by-case basis, as with any biologic.

Cost and Insurance Realities

Biologic drugs for eczema are expensive, and Adbry is no exception. The list price runs into the tens of thousands of dollars per year, similar to dupilumab. However, a budget-impact analysis modeled what happens when Adbry becomes available as an additional option within a health plan’s formulary. Having Adbry as an alternative led to cumulative savings of about $3.4 million over three years across a hypothetical plan, reducing per-patient treatment costs by roughly $5,000 over that period.²³ The savings come partly from Adbry’s lower net cost compared with some competing biologics and partly from the option to reduce dosing frequency to every four weeks in responders.

In practice, your out-of-pocket cost depends heavily on your insurance plan and whether you use the manufacturer’s copay assistance program. Most patients with commercial insurance can access copay cards that significantly reduce the monthly cost. For those on government insurance, the path can be more complicated, and prior-authorization requirements vary widely by plan. If cost is a barrier, working with a specialty pharmacy or your dermatologist’s office to navigate appeals and assistance programs is often the difference between access and going without.